Development and validation of a high performance liquid chromatography assay for the determination of a fluorinated analogue of thalidomide, n-(2,6-dioxopiperidin-3-yl)-3,4,5,6-tetrafluorophthalamic acid, and lenalidomide

Journal of Liquid Chromatography and Related Technologies

Volumn 34, Issue 2, 2011, Pages 83-92

  Pather, Kaveshree ^a   Helsby, Nuala A ^b   Palmer, Brian D ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

anti angiogenic; lenalidomide; multiple myeloma; pharmacokinetics; phthalamic acid

Indexed keywords

ANTI-ANGIOGENIC; AREA UNDER THE CURVES; C57BL/6 MICE; CLINICAL USE; CONCENTRATION RANGES; FLUORINATED DERIVATIVES; FREEZING AND THAWING; INTRAPERITONEAL; INTRAPERITONEAL ADMINISTRATION; LENALIDOMIDE; LOWER LIMIT OF QUANTIFICATIONS; MULTIPLE MYELOMA; PHTHALAMIC ACID; PLASMA CONCENTRATION; RELATIVE STANDARD DEVIATIONS; SECOND GENERATION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

PHARMACOKINETICS;

DIMETHYL SULFOXIDE; LENALIDOMIDE; N (2,6 DIOXOPIPERIDIN 3 YL) 3,4,5,6 TETRAFLUOROPHTHALAMIC ACID; SN 29900; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD LEVEL; DRUG ADMINISTRATION ROUTE; DRUG DETERMINATION; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SOLUTION AND SOLUBILITY; STORAGE; THAWING; VALIDATION STUDY;

MUS;

EID: 78651355662     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826076.2010.526853     Document Type: Article

References (12)

1. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C., Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumour Activity of Thalidomide in Refractory Multiple Myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
2. Barlogie, B.; Shaughnessy, J.; Tricot, G.; Jacobson, J.; Zangari, M.; Anaissie, E.; Walker, R.; Crowley, J. Treatment of Multiple Myeloma. Blood. 2004, 103, 20-32.
3. Rajkumar, S. V.; Hayman, S.; Gertz, M. A.; Dispenzieri, A.; Lacy, M. Q.; Greipp, P. R.; Geyer, S.; Iturria, N.; Fonseca, R.; Lust, J. A.; Kyle, R. A.; Witzig, T. E. Combination Therapy with Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. J. Clin. Oncol. 2002, 20, 4319-4323.
4. Richardson, P. G.; Schlossman, R. L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F. et al. Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug Resistance and is Well Tolerated in Patients with Relapsed Multiple Myeloma. Blood. 2002,100, 3063-3067.
5. Bartlett, J. B.; Dredge, K.; Dalgleish, A. G. The Evolution of Thalidomide and Its IMiD Derivatives as Anticancer Agents. Nat. Rev. Cancer. 2004, 4, 314-322.
6. Dredge, K.; Marriot, J. B.; MacDonald, C. D.; Man, H. W.; Chen, R.; Muller, G. W.; Stirling, D.; Dalgleish, A. G. Novel Thalidomide Analogues Display Anti-Angiogenic Activity Independently of Immunomodulatory Effects. Br. J. Cancer. 2002, 87, 1166-1172.
7. Mitsiades, C. S.; Hayden, P. J.; Anderson, K. C.; Richardson, P. G. Apoptotic Signaling Induced by Immunomodulatory Thalidomide Analogs in Human Multiple Myeloma Cells: Therapeutic Implications. Best Pract. Res. Clin. Haematol. 2007, 20, 797-816.
8. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T. et al. Apoptotic Signaling Induced By Immunomodulatory Thalidomide Analogs in Human Multiple Myeloma Cells: Therapeutic Implications. Blood, 2002, 99, 4525-4530.
9. Niwayama, S.; Turk, B. E.; Liu, J. O. Potent Inhibition of Tumor Necrosis Factor-a Production by Tetrafluorothalidomide and Tetrafluorophthalimides. J. Med. Chem. 1996, 39, 3044-3045.
10. Niwayama, S.; Loh, C.; Turk, B. E.; Jun, L. O.; Miyachi, H.; Hashimoto, Y. Enhanced Potency of Perfluorinated Thalidomide Derivatives for Inhibition of LPS-induced Tumor Necrosis Factor-a Production is Associated with a Change of Mechanism of Action. Bioorg. Med. Chem. Lett. 1998, 8, 1071-1076.
11. Muller, G. W.; Stirling, D. I.; Chen, R. US patent 5635517, 1997.
12. Palmer, B. D.; Ching, L.-M. Patent Application WO 2008007979, 2008.